Table 2 Current pharmaceutical disease-modifying clinical trials phase II and III
Τargeting mechanism | ClinTrial indentifier | Drug | Phase | Τarget population | Primary outcome | Other secondary outcomes of interest | Sponsor |
|---|---|---|---|---|---|---|---|
A2Α receptor antagonists | NCT03703570 | KW-6356 | II | PD | Changes in MDS-UPDRS part III | . | Kyowa Kirin Co., Ltd. |
NCT02939391 | KW-6356 | II | Early PD | Changes in MDS-UPDRS part III | . | Kyowa Kirin Co., Ltd. | |
Calcium Targeting Therapies | NCT02168842 | Isradipine | III | Early PD | Changes in MDS UPDRS Part I-III | . | University of Rochester |
Glucagon-like peptide 1 receptor agonists and other antidiabetic agents | NCT03659682 | Semaglutide | II | Early PD | Changes in MDS-UPDRS part 3 in OFF medication state | . | Oslo University Hospital |
NCT02953665 | Liraglutide | II | Early PD | Motor Function, Non-Motor Function, Cognitive Function | . | Cedars-Sinai Medical Center | |
NCT03439943 | Lixisenatide | II | Early PD | Changes in MDS-UPDRS Part III in ON status | . | University Hospital, Toulouse | |
NCT04305002 | Εxenatide | II | Early PD | Changes in FDG-PET network analysis | Changes in MDS-UPDRS Part III in ON and OFF status | Center for Neurology, Stockholm Karolinska Institutet | |
NCT04154072 | NLY01 | ΙΙ | Early Treatment Naïve PD | Changes in MDS UPDRS Part II-III | . | Neuraly, Inc | |
NCT04232969 | Εxenatide | III | PD | Changes in MDS-UPDRS part III in OFF medication state | . | University College, London | |
NCT04269642 | Εxenatide | II | Early PD | Changes in MDS-UPDRS part III score | Changes in SNBR confirmed by PET scan | Peptron, Inc. | |
Glucocerebrosidase targeting therapies | NCT02914366 | Αmbroxol | II | PD Dementia | Changes in ADAS-cog and ADCS-CGIC scales | Changes in MRI biomarkers | Lawson Health Research Institute |
NCT02906020 | GZ/SAR402671 | II | Patients with Early PD Carrying a GBA Gene Mutation | Number of Patients with AE, Changes in UPDRS Part II and III during OFF state | . | Genzyme, a Sanofi Company | |
NCT04127578 | PR001A | I/II | Patients with PD With at Least One GBA1 Mutation | Number of TEAEs and SAEs | . | Prevail Therapeutics | |
Targeting α-synuclein: Immunotherapies | NCT03100149 | RO7046015/ PRX002 | II | Early PD | Changes in MDS-UPDRS total score | Changes in DaT-SPECT | Hoffmann-La Roche |
NCT03318523 | BIIB054 | II | PD | Changes in MDS-UPDRS total score | Change in SBR measured by SPECT/DATSCAN | Biogen | |
Targeting α-synuclein: prevention of aggregation | NCT03655236 | K0706 | II | Early PD | Changes in MDS UPDRS Part II-III | Changes in DaT-SPECT | Sun Pharma Advanced Research Company Limited |
Ιron Targeting Therapies | NCT02655315 | Deferiprone | II | Treatment Naive PD | Changes in total MDS-UPDRS | . | University Hospital, Lille European Commission ApoPharma |